Co-Diagnostics Reports Third Quarter 2026 Financial Results
PR Newswire•10/11/2026•08:00 ET
0
Key Highlights
- ➤Two regulatory submissions under review in India and U.S.: CoSara PCR MTB and Flu A/B & RSV
- ➤Revenue $0.3 million, compared with $0.1 million in Q3 2025
- ➤Operating expenses $6.2 million, down 12% year over year
- ➤Cash $0.7 million; secured convertible financing added approximately $2.1 million after quarter-end
- ➤CoSara PCR MTB showed 97.3% average sensitivity and 96.0% specificity across 233 samples
Expert Statements
Dwight Egan, Chief Executive Officer of Co-Diagnostics
“The third quarter was a period of significant regulatory and operational progress for Co-Diagnostics. CoSara completed its clinical performance study for our point-of-care tuberculosis test and submitted it to India's Central Drugs Standard Control Organization (CDSCO), and together with our August FDA 510(k) submission for the Flu A/B & RSV test, we now have two regulatory submissions under review in two important markets for our platform. We also launched our cloud and mobile infrastructure in India, began evaluating blood-based testing with ReadyGo, and completed the first international deployment of Vector Smart. With our submissions in India and the U.S. under review, our focus is on supporting those reviews, advancing our feasibility work with ReadyGo and continuing to grow Vector Smart.”
Co-Diagnostics Reports Third Quarter 2026 Financial Results PR Newswire
Two Regulatory Submissions Under Review in India and the U.S.
Get started
Create a free account to read the full story.